Extended Data Fig. 7: Outcome according to triple combination of baseline biomarkers for the conformation-cohort OpACIN-neo. | Nature Medicine

Extended Data Fig. 7: Outcome according to triple combination of baseline biomarkers for the conformation-cohort OpACIN-neo.

From: Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial

Extended Data Fig. 7

a, Bar plot showing the percentage of patients achieving MPR (including 95% confidence interval) sub grouped according to the combination of the three biomarkers: low TMB, low IFNγ and low PD-L1 (n = 11); low TMB, low IFNγ and high PD-L1 (n = 4); high TMB, low IFNγ and low PD-L1 (n = 8); low TMB, high IFNγ and low PD-L1 (n = 4); high TMB, high IFNγ and low PD-L1 (n = 4); low TMB, high IFNγ and high PD-L1 (n = 4); high TMB, low IFNγ and high PD-L1 (n = 6); high TMB, high IFNγ and high PD-L1 (n = 3). b, Kaplan Meier curve, including log-rank P value for event free survival, according to the three biomarker subgroups as described in a. c, ROC curves for low TMB, low IFNγ and low PD-L1 versus other biomarker combinations (AUC = 0.701) and for high TMB, high IFNγ and high PD-L1 versus the other biomarker combinations (AUC = 0.776). ROC curve analyses used a binary outcome (event within five years), since follow-up among all event-free patients was ≥58. d,e, Kaplan Meier curves, including log-rank P value for event free survival of patients with low IFNγ, low TMB and low PD-L1 (n = 11) versus all other biomarker combinations (n = 33) (d), and of patients with high IFNγ, high TMB and high PD-L1 (n = 3) versus all other biomarker combinations (n = 41) (e).

Back to article page